Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18+
SponsorEmory University
About this trial
This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.
Eligibility criteria
Qualifiers
Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy
Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
There will be no limitations on number of prior lines of therapy
Trial is open to non-English speaking patients
Disqualifiers
Patients who are < 18 years old
Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive)
Patients who are incarcerated
Patients who are unable to provide consent / lack decision-making capacity
Trial design
Treatments tested in this trial
- Atovaquone
- Biopsy
- Computed Tomography
- Paracentesis
Treatment groups
28 Participants
are divided into 1 treatment groupSponsors and collaborators
Emory University
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov